ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Cellectis S.A. - American Depositary Shares (CLLS)
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cellectis.com/en/investors
Company Research
Source: GlobeNewswire
Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after =2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistenceIL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced the presentation of encouraging updated data of patients treated in the Phase 1 NATHALI-01 clinical trial with eti-cel, at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. Eti-cel product candidate is the first allogeneic dual CAR-T targeting CD20 and CD22 simultaneously, being developed in Phase 1 of the NATHALI-01 clinical trial, for patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL), following
Show less
Read more
Impact Snapshot
Event Time:
CLLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CLLS
News
- Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem CellsGlobeNewswire
- Cellectis GAAP EPS of $0.01 beats by $0.24, revenue of $37.16M [Seeking Alpha]Seeking Alpha
- Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cellectis Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Cellectis to Present a Development Update for eti-cel at ASH 2025GlobeNewswire
CLLS
Earnings
- 3/13/25 - Miss
CLLS
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/8/25 - Form 6-K
- 12/5/25 - Form 6-K
- CLLS's page on the SEC website